Clinical trial · Observational
Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer
NCT01199393CI-TRIAL-00018692completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators want to research whether genetic polymorphisms of drug-metabolizing enzymes can be used to predict chemotherapeutic outcomes in patients with metastatic breast cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasm | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Drug Therapy | — | UNRESOLVED | — |
| Polymorphism,Single Nucleotide | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response to chemotherapy
- timeFrame
- 6 months
- description
- Response to chemotherapy is evaluated by Response Evaluation Criteria in Solid Tumors(RESIST).
Secondary outcomes (3)
- measure
- Time to disease progression
- timeFrame
- 1 year
- description
- Time to disease progression is measured from the date therapy is initiated to the date of documented disease progression.
- measure
- Overall survival
- timeFrame
- 5 years
- description
- Overall survival is measured from the date therapy is initiated to the date of death or final follow-up.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed metastatic breast cancer * Female * An Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * At least one measurable lesion * Normal cardiac, hepatic, renal and bone marrow functions * Life expectancy ≥3 months * Discontinuity of previous chemotherapy for a minimum of 4 weeks Exclusion Criteria: * Central nervous system metastases * Serious or uncontrolled concurrent medical illness * History of other malignancies
References
Publications (0)
Data not yet available
No reference posted for this study.